Resonant nonstationary amplification of polychromatic laser pulses and conical emission in an optically dense ensemble of neon metastable atoms

Experimental and numerical investigation of single-beam and pump-probe interaction with a resonantly absorbing dense extended medium under strong and weak field-matter coupling is presented. Significant probe beam amplification and conical emission were observed. Under relatively weak pumping and high medium density, when the condition of strong coupling between field and resonant matter is fulfilled, the probe amplification spectrum has a form of spectral doublet. Stronger pumping leads to the appearance of a single peak of the probe beam amplification at the transition frequency. The greater probe intensity results in an asymmetrical transmission spectrum with amplification at the blue wing of the absorption line and attenuation at the red one. Under high medium density, a broad band of amplification appears. Theoretical model is based on the solution of the Maxwell-Bloch equations for a two-level system. Different types of probe transmission spectra obtained are attributed to complex dynamics of a coherent medium response to broadband polychromatic radiation of a multimode dye laser.Comment: 9 pages, 13 figures, corrected, Fig.8 was changed, to be published in Phys. Rev.

Primitivism and the writers of the Irish dramatic movement to 1910

SIGLEAvailable from British Library Document Supply Centre-DSC:D198237 / BLDSC - British Library Document Supply CentreGBUnited Kingdo

Supplementary Material for: Predicting the Glomerular Filtration Rate in Bariatric Surgery Patients

<b><i>Background/Aims:</i></b> Identifying the best method to estimate the glomerular filtration rate (GFR) in bariatric surgery patients has important implications for the clinical care of obese patients and research into the impact of obesity and weight reduction on kidney health. We therefore performed such an analysis in patients before and after surgical weight loss. <b><i>Methods:</i></b> Fasting measured GFR (mGFR) by plasma iohexol clearance before and after bariatric surgery was obtained in 36 severely obese individuals. Estimated GFR was calculated using the Modification of Diet in Renal Disease equation, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation using serum creatinine only, the CKD-EPI equation using serum cystatin C only and a recently derived equation that uses both serum creatinine and cystatin C (CKD-EPI_creat-cystC) and then compared to mGFR. <b><i>Results:</i></b> Participants were primarily middle-aged white females with a mean baseline body mass index of 46 ± 9, serum creatinine of 0.81 ± 0.24 mg/dl and mGFR of 117 ± 40 ml/min. mGFR had a stronger linear relationship with inverse cystatin C before (r = 0.28, p = 0.09) and after (r = 0.38, p = 0.02) surgery compared to the inverse of creatinine (before: r = 0.26, p = 0.13; after: r = 0.11, p = 0.51). mGFR fell by 17 ± 35 ml/min (p = 0.007) following surgery. The CKD-EPI_creat-cystC was unquestionably the best overall performing estimating equation before and after surgery, revealing very little bias and a capacity to estimate mGFR within 30% of its true value over 80% of the time. This was true whether or not mGFR was indexed for body surface area. <b><i>Conclusions:</i></b> In severely obese bariatric surgery patients with normal kidney function, cystatin C is more strongly associated with mGFR than is serum creatinine. The CKD-EPI_creat-cystC equation best predicted mGFR both before and after surgery

Treatment options for nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) has become increasingly recognized as the most common cause of abnormal liver enzymes in the last few decades and is among the most common forms of chronic liver disease in the Western world and across the globe. With the growing epidemic of obesity and diabetes, NAFLD is estimated to affect about one-quarter of the US population. Although most patients with NAFLD have nonprogressive bland steatosis, a minority of patients develop the histological subtype of nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis, hepatocellular carcinoma, and liver-related death. This is especially true when NASH patients have type 2 diabetes. Treatment of NAFLD should therefore be directed towards patients with established NASH. Sustained weight loss seems to improve insulin resistance and associated NASH. In fact, weight loss with bariatric surgery leads to biochemical and histological improvement in morbidly obese patients with NASH. Several pharmacologic agents have been studied in an effort to improve insulin resistance and pro-inflammatory mediators potentially responsible for the development and progression of NASH. While some studies have shown initial promise, none has established long-term efficacy using randomized clinical trials. This paper briefly reviews the epidemiology, natural history, and pathophysiology of NAFLD and NASH and then focuses on the clinical trials of various therapeutic modalities for NAFLD. These include weight loss agents, bariatric surgery, insulin-sensitizing agents, lipid-lowering agents, antioxidants, probiotics, anti-tumor necrosis factor agents, cytoprotective and other novel agents